Institut für Anorganische und Analytische Chemie Friedrich-Schiller-Universität Jena, Humboldstraße 8, 07743 Jena, Germany.
Dalton Trans. 2019 Jan 15;48(3):936-944. doi: 10.1039/c8dt02553c.
After more than 50 years of platinum-based anticancer research only three compounds are in clinical use worldwide. The use of the well-known lead compound of this class of anticancer agents, cisplatin, is limited by its side effects and varying resistance mechanisms. Therefore, we report on platinum(ii) compounds with asparagusic acid derivatives as ligands which show interesting anticancer results on cisplatin resistant cell lines.
经过超过 50 年的基于铂的抗癌研究，全球仅有三种化合物在临床应用。由于其副作用和不同的耐药机制，广泛应用的这类抗癌药物的先导化合物顺铂受到限制。因此，我们报告了以天门冬氨酸衍生物为配体的铂（II）化合物，这些化合物在顺铂耐药细胞系中显示出有趣的抗癌效果。
